Lofiego, Maria Fortunata
Piazzini, Francesca
Caruso, Francesca Pia
Marzani, Francesco
Solmonese, Laura
Bello, Emma
Celesti, Fabrizio
Costa, Maria Claudia
Noviello, Teresa
Mortarini, Roberta
Anichini, Andrea
Ceccarelli, Michele
Coral, Sandra
Di Giacomo, Anna Maria
Maio, Michele
Covre, Alessia http://orcid.org/0000-0001-8721-5693
,
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (5 per Mille 2018 - ID.21073)
Article History
Received: 22 December 2023
Accepted: 24 February 2024
First Online: 1 March 2024
Declarations
:
: Not applicable.
: Not applicable.
: AMDG has served as consultant and/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre and Sanofi. MM has served as consultant and/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and own shares in Theravance and Epigen Therapeutics, Srl. MC serves as consultant and/or advisor to Moderna Therapeutics and is founder and owns shares of Immunomica srl. Other authors have nothing to declare.